Multipl Sklerozda İmmünsupresif Tedaviler

Tafti D, Ehsan M, Xixis KL. Multiple Sclerosis. StatPearls. Treasure Island (FL) ineligible companies.: StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.; 2025.

Filippi M, Amato MP, Centonze D, et al. Early use of high-efficacy disease modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. Journal of neurology. 2022;269(10):5382-94.

Jonuleit H, Schmitt E, Steinbrink K, et al. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends in immunology. 2001;22(7):394-400.

Lorenzut S, Negro ID, Pauletto G, et al. Exploring the Pathophysiology, Diagnosis, and Treatment Options of Multiple Sclerosis. Journal of integrative neuroscience. 2025;24(1):25081.

Jäger A, Dardalhon V, Sobel RA, et al. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. Journal of immunology (Baltimore, Md : 1950). 2009;183(11):7169-77.

Lublin FD, Coetzee T, Cohen JA, et al. The 2013 clinical course descriptors for multiple sclerosis: A clarification. Neurology. 2020;94(24):1088-92.

Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. The American journal of medicine. 2020;133(12):1380-90.e2.

Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86.

Kleiter I, Ayzenberg I, Havla J, et al. The transitional phase of multiple sclerosis: Characterization and conceptual framework. Multiple sclerosis and related disorders. 2020;44:102242.

Ridley B, Minozzi S, Gonzalez-Lorenzo M, et al. Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. The Cochrane database of systematic reviews. 2024;9(9):Cd015443.

Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis: insights from pathology. Current opinion in neurology. 2014;27(3):271-8.

Willis MA, Fox RJ. Progressive Multiple Sclerosis. Continuum (Minneapolis, Minn). 2016;22(3):785-98.

Ziemssen T, Bhan V, Chataway J, et al. Secondary progressive multiple sclerosis: a review of clinical characteristics, definition, prognostic tools, and disease-modifying therapies. Neurology: Neuroimmunology & Neuroinflammation. 2022;10(1):e200064.

Garton T, Gadani SP, Gill AJ, et al. Neurodegeneration and demyelination in multiple sclerosis. Neuron. 2024.

Lambe J, Ontaneda D. Re-defining progression in multiple sclerosis. Current opinion in neurology. 2025;38(3):188-96.

Tur C, Rocca MA. Progression Independent of Relapse Activity in Multiple Sclerosis: Closer to Solving the Pathologic Puzzle. Neurology. 2024;102(1):e207936.

Albelo-Martínez M, Rizvi S. Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2025:e00601.

Cree BA, Arnold DL, Chataway J, et al. Secondary progressive multiple sclerosis: new insights. Neurology. 2021;97(8):378-88.

Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron. 2018;97(4):742-68.

Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World journal of clinical cases. 2015;3(7):545-55.

Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nature reviews Neurology. 2012;8(11):647-56.

Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016;87(20):2074-81.

Vermersch P, Brieva-Ruiz L, Fox RJ, et al. Efficacy and safety of masitinib in progressive forms of multiple sclerosis: a randomized, phase 3, clinical trial. Neurology: Neuroimmunology & Neuroinflammation. 2022;9(3):e1148.

Mohammed EMA. Understanding Multiple Sclerosis Pathophysiology and Current Disease-Modifying Therapies: A Review of Unaddressed Aspects. Frontiers in bioscience (Landmark edition). 2024;29(11):386.

Androdias G, Lünemann JD, Maillart E, et al. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain : a journal of neurology. 2025;148(5):1459-78.

Okuda DT. Immunosuppressive treatments in multiple sclerosis. Handbook of clinical neurology. 2014;122:503-11.

AlShamrani FJ. Cyclophosphamide as initial treatment of aggressive MS (Marburg variant) in resource limited settings - A case report. Clinical neurology and neurosurgery. 2025;252:108857.

Neuhaus O, Kieseier BC, Hartung HP. Immunosuppressive agents in multiple sclerosis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2007;4(4):654-60.

Mariottini A, Muraro PA, Lünemann JD. Antibody-mediated cell depletion therapies in multiple sclerosis. Frontiers in immunology. 2022;13:953649.

Alping P, Burman J, Lycke J, et al. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology. 2021;96(11):e1574-e84.

Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2013;19(5):593-600.

Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology. 2017;89(11):1117-26.

Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer chemotherapy and pharmacology. 2016;78(4):661-71.

Gómez-Figueroa E, Gutierrez-Lanz E, Alvarado-Bolaños A, et al. Cyclophosphamide treatment in active multiple sclerosis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2021;42(9):3775-80.

Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993;43(5):910-8.

Fereidan-Esfahani M, Tobin WO. Cyclophosphamide in treatment of tumefactive multiple sclerosis. Multiple sclerosis and related disorders. 2021;47:102627.

Hohol MJ, Olek MJ, Orav EJ, et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Multiple sclerosis (Houndmills, Basingstoke, England). 1999;5(6):403-9.

Portaccio E, Zipoli V, Siracusa G, et al. Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort. Multiple sclerosis (Houndmills, Basingstoke, England). 2003;9(5):446-50.

Stankiewicz JM, Kolb H, Karni A, et al. Role of immunosuppressive therapy for the treatment of multiple sclerosis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2013;10(1):77-88.

Cronstein BN. The mechanism of action of methotrexate. Rheumatic diseases clinics of North America. 1997;23(4):739-55.

Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nature reviews Rheumatology. 2020;16(3):145-54.

Kolb H, Shachaf Y, Fainberg K, et al. Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up. Journal of neurology. 2025;272(5):374.

Bleyer WA, Dedrick RL. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer treatment reports. 1977;61(4):703-8.

Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. The Journal of clinical investigation. 2003;111(8):1133-45.

Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. The Cochrane database of systematic reviews. 2007;2007(4):Cd003982.

Ridley B, Nonino F, Baldin E, et al. Azathioprine for people with multiple sclerosis. The Cochrane database of systematic reviews. 2024;12(12):Cd015005.

Frohman EM, Brannon K, Racke MK, et al. Mycophenolate mofetil in multiple sclerosis. Clinical neuropharmacology. 2004;27(2):80-3.

Barten MJ, van Gelder T, Gummert JF, et al. Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo. Transplant immunology. 2002;10(1):1-14.

Chedid T, Moisset X, Clavelou P. Rationale for off-label treatments use in primary progressive multiple sclerosis: A review of the literature. Revue neurologique. 2022;178(9):932-8.

Frohman EM, Cutter G, Remington G, et al. A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Therapeutic advances in neurological disorders. 2010;3(1):15-28.

Zinzani PL, Buzzi M, Farabegoli P, et al. Apoptosis induction with fludarabine on freshly isolated chronic myeloid leukemia cells. Haematologica. 1994;79(2):127-31.

Greenberg SJ, Zivadinov R, Lee-Kwen P, et al. Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease. Therapeutic advances in neurological disorders. 2016;9(2):105-17.

Loh SMY, Ratnagopal P, Tan HCP, et al. Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning. International journal of hematology. 2006;83(4):368.

Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004;63(12 Suppl 6):S15-8.

Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet (London, England). 2002;360(9350):2018-25.

Gajofatto A, Turatti M, Monaco S, et al. Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drug, healthcare and patient safety. 2015;7:157-67.

Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature reviews Drug discovery. 2010;9(11):883-97.

Hatcher SE, Waubant E, Graves JS. Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation-Reply. JAMA neurology. 2016;73(11):1376.

Scott LJ. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis. Drugs. 2019;79(8):875-86.

Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology. 2014;13(3):247-56.

O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. The New England journal of medicine. 2011;365(14):1293-303.

Lehto J, Nylund M, Matilainen M, et al. Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis. European journal of neurology. 2023;30(8):2365-75.

Miller AE. An updated review of teriflunomide's use in multiple sclerosis. Neurodegenerative disease management. 2021;11(5):387-409.

Sprenger T, Kappos L, Radue EW, et al. Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide. Multiple sclerosis (Houndmills, Basingstoke, England). 2020;26(10):1207-16.

Sellner J, Rommer PS. Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review. Autoimmunity reviews. 2020;19(4):102492.

Derfuss T, Mehling M, Papadopoulou A, et al. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. The Lancet Neurology. 2020;19(4):336-47.

AlSharoqi IA, Aljumah M, Bohlega S, et al. Immune reconstitution therapy or continuous immunosuppression for the management of active relapsing–remitting multiple sclerosis patients? A narrative review. Neurology and Therapy. 2020;9:55-66.

Giovannoni G, Mathews J. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review. Neurol Ther. 2022;11(2):571-95.

Buttari F, Dolcetti E, Rizzo FR, et al. Cladribine tablets in the new multiple sclerosis era. Therapeutic advances in neurological disorders. 2025;18:17562864251342855.

Buc M. New biological agents in the treatment of multiple sclerosis. Bratislavske lekarske listy. 2018;119(4):191-7.

Boster A, Edan G, Frohman E, et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. The Lancet Neurology. 2008;7(2):173-83.

Le Page E, Edan G. Induction or escalation therapy for patients with multiple sclerosis? Revue neurologique. 2018;174(6):449-57.

Pöhlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Multiple sclerosis (Houndmills, Basingstoke, England). 2007;13(9):1107-17.

Brandt-Wouters E, Gerlach OH, Hupperts RM. The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2016;134(2):194-6.

Bascić-Kes V, Kes P, Zavoreo I, et al. Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases. Acta clinica Croatica. 2012;51(4):673-83.

Mariottini A, De Matteis E, Cencioni MT, et al. Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances. Current neurology and neuroscience reports. 2023;23(9):507-20.

Sormani MP, Muraro PA, Schiavetti I, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. Neurology. 2017;88(22):2115-22.

Shipley J, Beharry J, Yeh W, et al. Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1. The Medical journal of Australia. 2025;222(7):356-64.

Mariottini A, Bulgarini G, Forci B, et al. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis. European journal of neurology. 2022;29(6):1708-18.